|  |  |  |  |
| --- | --- | --- | --- |
| 1-4 | 145 | Neutral, but male at risk (in subgroup) | (115) |
| 1-5 | 133 | Male at risk | (63) |
| 2-3 | 2070 | Neutral | (87) |
| 2-3A | 1908 | Male at risk | (103) |
| 2-4 | 72 | Neutral | (107) |
| 2-5 | 117 | Male at risk | (33) |
| 3 | 120 | Male at risk | (19) |
| 3-4 | 178 | Male at risk | (23) |
| 3-4 | 84 | Neutral for overall risk but | (40) |
|  |  | male at risk for severe disease |
| 3-4 | 112 | Male at risk | (99) |
| 3-4 | 112 | Male at risk for progression | (125) |
| 3-5 | 562 | Male at risk but not for progression | (94) |
| 4-5D | 134 | Male at risk for progression | (77) |
| 4-5D | 134 | Male at risk | (124) |
| 5 | 152 | Male at risk | (91) |
| 5, 5D | 149 | Male at risk | (109) |
| 5, 5D,5T | 261 | Neutral | (129) |
| 5D | 142 | Male at risk (subgroup) | (102) |
| 5D | 232 | Neutral | (22) |
| 5D | 140 | Neutral | (110) |
| 5D | 61 | Male at risk | (111) |
| 5D | 140 | Neutral | (123) |
| 5D | 135 | Neutral | (126) |
| 5D (HD) | 123 | Male at risk for severe disease | (88) |
| 5D (HD) | 129 | Neutral | (104) |
| 5D (HD) | 81 | Neutral | (106) |
| 5D (HD) | 360 | Male at risk for severe disease | (92) |
| 5D (HD) | 314 | Neutral | (108) |
| 5D (HD) | 594 | Male at risk | (112) |
| 5D (HD) | 421 | Male at risk (subgroup) | (113) |
| 5D (HD) | 90 | Male at risk and for severe disease | (38) |
| 5D (HD) | 90 | Male at risk for severe disease | (39) |
| 5D (HD) | 161 | Neutral | (42) |
| 5D (HD) | 85 | Neutral | (43) |
| 5D (HD) | 40 | Male at risk for progression | (114) |
| 5D (HD) | 309 | Female at risk | (95) |
| 5D (HD) | 81 | Male at risk | (97) |
| 5D (HD) | 148 | Neutral | (98) |
| 5D (HD) | 47 | Male at risk | (116) |
| 5D (HD) | 207 | Neutral | (117) |
| 5D (HD) | 332 | Male at risk | (118) |
| 5D (HD) | 216 | Female at risk | (65) |
| 5D (HD) | 184 | Male at risk for progression | (68) |
| 5D (HD) | 24 | Male at risk progression | (119) |
| 5D (HD) | 81 | Neutral | (120) |
| 5D (HD) | 205 | Differential effect depending on calcification site | (121) |
| 5D (HD) | 212 | Male at risk | (75) |
| 5D (HD) | 194 | Male at risk | (122) |
| 5D (HD) | 212 | Male at risk | (75) |
| 5D (HD) | 127 | Male at risk for progression | (127) |
| 5D (HD) | 224 | Male at risk | (81) |
| 5D (HD) | 191 | Male at risk | (128) |
| 5D (HD) | 108 | Neutral | (100) |
| 5D (HD) | 77 | Male at risk | (101) |
| 5D (HD) | 49 | Male at risk | (130) |
| 5D, 5T | 240 | Male at risk | (15) |
| 5D, 5T | 100 | Male at risk | (59) |
| 5T | 268 | Male at risk | (105) |
| 5T | 197 | Differential effect depending on calcification site | (96) |
| 5T | 50 | Neutral | (61) |
| 5T | 89 | Differential effect depending on calcification site | (70) |
| 5T | 99 | Male at risk | (76) |
| Proteinuric (1-5) | 225 | Male at risk | (17) |